1-2 of 2
Beth Maddox, RN
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I/II Trial of High-Dose Melphalan (M) and Topotecan (T) Followed by Autologous Stem Cell Rescue in Patients ≤ 60 and > 60 Years of Age with Multiple Myeloma (MM).

Daniel Sullivan, MD, Melissa Alsina, MD, Claudio Anasetti, MD, Teresa Field, MD, PhD, Mohamed Kharfan-Dabaja, MD, Hugo Fernandez, MD, William Dalton, PhD, MD, Ernesto Ayala, MD, Jyoti Raychaudhuri, MD, Lia Perez, MD, Janelle Perkins, PharmD, Michael Schell, PhD, Christine McIsaac, RN, Beth Maddox, RN, Jana Gump, BS, Richard Lush, PhD, Tony Frudakis, PhD
Journal: Blood
Blood (2007) 110 (11): 943.
https://doi.org/10.1182/blood.V110.11.943.943
Published: 2007
Journal Articles

Phase I Study of Bortezomib, (BTZ) Followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL).

Todd Alekshun, MD, Christine Mcisaac-Simonelli, RN, Mohamed Kharfan-Dabaja, MD, William Dalton, MD, PhD, Benjamin Djulbegovic, MD, Hugo Fernandez, MD, Daniel M. Sullivan, MD, Ernesto Ayala, MD, Teresa L. Field, MD, Dawn Garrett, LPN, William E. Janssen, PhD, Beth Maddox, RN, Lia Perez, MD, Dawn Kettner, PA, Janelle Perkins, PharmD, Jyoti Raychaudhuri, MD, Claudio Anasetii, MD, Melissa Alsina, MD
Journal: Blood
Blood (2007) 110 (11): 5131.
https://doi.org/10.1182/blood.V110.11.5131.5131
Published: 2007